Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Free Cash Flow (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Free Cash Flow readings, the most recent being -$13.9 million for Q1 2026.

  • Quarterly Free Cash Flow fell 35.2% to -$13.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$41.9 million through Mar 2026, up 15.52% year-over-year, with the annual reading at -$38.3 million for FY2025, 31.66% up from the prior year.
  • Free Cash Flow hit -$13.9 million in Q1 2026 for Ovid Therapeutics, down from -$10.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$4.8 million in Q2 2025 and bottomed at -$20.1 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$12.4 million, with a median of -$11.9 million recorded in 2023.
  • The largest annual shift saw Free Cash Flow plummeted 112.5% in 2022 before it soared 66.59% in 2025.
  • Ovid Therapeutics' Free Cash Flow stood at -$10.1 million in 2022, then decreased by 17.49% to -$11.9 million in 2023, then increased by 16.29% to -$10.0 million in 2024, then fell by 3.93% to -$10.4 million in 2025, then plummeted by 33.98% to -$13.9 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Free Cash Flow are -$13.9 million (Q1 2026), -$10.4 million (Q4 2025), and -$12.9 million (Q3 2025).